Cognitive impairment in early MS: contribution of white matter lesions, deep grey matter atrophy, and cortical atrophy

Christina Engl1,2 · Laura Tiemann1,2 · Sophia Grahl1,2 · Matthias Bussas1,2 · Paul Schmidt1,2 · Viola Pongratz1,2 · Achim Berthele1 · Annkathrin Beer1,2 · Christian Gaser3 · Jan S. Kirschke4 · Claus Zimmer4 · Bernhard Hemmer1,5 · Mark Mühlau1,2

Received: 30 December 2019 / Revised: 27 March 2020 / Accepted: 14 April 2020 / Published online: 23 April 2020 © The Author(s) 2020

Abstract
Background Cognitive impairment (CI) is a frequent and debilitating symptom in MS. To better understand the neural bases of CI in MS, this magnetic resonance imaging (MRI) study aimed to identify and quantify related structural brain changes and to investigate their relation to each other.

Methods We studied 51 patients with CI and 391 patients with cognitive preservation (CP). We analyzed three-dimensional T1-weighted and FLAIR scans at 3 Tesla. We determined mean cortical thickness as well as volumes of cortical grey matter (GM), deep GM including thalamus, cerebellar cortex, white matter, corpus callosum, and white matter lesions (WML). We also analyzed GM across the whole brain by voxel-wise and surface-based techniques.

Results Mean disease duration was 5 years. Comparing MS patients with CI and CP, we found higher volumes of WML, lower volumes of deep and cortical GM structures, and lower volumes of the corpus callosum (all corrected p values < 0.05). Effect sizes were largest for WML and thalamic volume (standardized ß values 0.25 and −0.25). By logistic regression analysis including both WML and thalamic volume, we found a significant effect only for WML volume. Inclusion of the interaction term of WML and thalamic volume increased the model fit and revealed a highly significant interaction of WML and thalamic volume. Moreover, voxel-wise and surface-based comparisons of MS patients with CI and CP showed regional atrophy of both deep and cortical GM independent of WML volume and overall disability, but effect sizes were lower.

Conclusion Although several mechanisms contribute to CI already in the early stage of MS, WML seem to be the main driver with thalamic atrophy primarily intensifying this effect.

Keywords Cognitive impairment · Multiple sclerosis · White matter lesion · Thalamus

Introduction
Cognitive impairment (CI) is a common symptom in multiple sclerosis (MS). The neuropathological substrates of MS-related CI, and hence potential therapeutic targets, are still controversial [1]. One of the earliest magnetic resonance imaging (MRI) studies on CI in MS [2] reported a strong relationship between CI and white matter lesions (WML) compatible with the classic idea of a disconnection syndrome [3]. In later MRI studies, relations of CI to deep and cortical grey matter (GM) atrophy were reported [4–11]. When we, to the best of our knowledge, reviewed the ten structural brain MRI studies on CI in MS, with the highest numbers of CI patients included [4–13], we observed inconsistent results with regard to the contribution of WML load and GM atrophy to CI in MS. This seems well conceivable...
given the variety of methods used which hampers comparability. Some studies found only a contribution of WML [12, 13]. In these two studies, high-resolution structural images were not available, so that changes in GM, i.e., atrophy, may have been missed. Other studies identified GM atrophy as the main driver of CI in MS. One study found an association of deep and cortical GM atrophy through voxel-wise analysis of high-resolution T1-weighted images at 3 T [4], whilst WML volume did not differ between groups. However, patients groups were heterogeneous comprising patients with relapsing–remitting (n = 22), secondary progressive (n = 29), and primary progressive (n = 22) MS, which may have resulted in a high variance with regard to WML volume lowering statistical power. In another two studies, primarily thalamic atrophy [5, 6] was related to CI in MS. In one of the two studies, the methodology was focused on the thalamus. In a complex statistical model, only thalamus measures explained CI; of note, raw values of normalized brain volume, deep GM, and WML volume were also significantly different between groups [5]. In the other of the two studies, healthy controls were compared to patients with PPMS which showed lower cognitive test scores. This setting required a correlation of test performance with MRI-based measures only in the patients. Again, in a statistical model including several MRI parameters (stepwise linear regression), only thalamic volume showed a significant effect, whilst raw values of other parameters differed as well [6].

Further studies reported contributions of both WML load and GM atrophy [7–11]. However, in some of these studies, groups of patients with different degrees of CI also differed in other characteristics such as disease duration and EDSS, which was not accounted for statistically, so that results do not necessarily demonstrate differential contributions to CI [7, 8]. The same applies to a study on a large group of MS patients in which 43% were classified as CI and in which voxel-wise correlations of GM with scores of different tests were performed across the whole group [10]. In a study using high-resolution MRI, CI was related to WML and a loss of deep GM and, to a small degree, lower cortical thickness [9]. Moreover in a study on 1052 patients with MS, WML volume and brain parenchymal fraction could be analyzed. A weak correlation between CI and both MRI-based parameters was found in the early stages (< 2 years) and a strong correlation in later stages (> 15 years), whilst no differentiation between GM structures was possible. Finally, atrophy of the corpus callosum has also been related to CI, although based on a lower number of patients [14–17].

In this study, we retrospectively analyzed data from a large cohort of patients with MS primarily in early stages. All included patients underwent neuropsychological testing and standardized high-resolution MRI including FLAIR and T1-weighted sequences. These data enabled us to search for structural brain changes related to CI both at the global and regional level across the whole brain. Besides identifying brain structures, we could compare the sizes of their contributions, analyze their relation to each other, and search for differential contributions.

### Materials and methods

#### Data acquisition and cognition assessment

In accordance with the Declaration of Helsinki, the study was performed in the context of our prospective observational study TUM-MS, which was approved by the local ethics committee. In the context of TUM-MS, patients are followed up annually by standardized clinical and neuropsychological examinations and brain MRI. Tests include Expanded Disability Status Scale (EDSS) and cognitive screening tests, including the Multiple Sclerosis Inventory Cognition (MuSIC) [18, 19]. MuSIC consists of 5 subtests to assess the cognitive core deficits in MS: attention and memory are tested first by ‘word list A’ (immediate recall of ten spoken words performed twice), second by ‘word list B’ (immediate recall of ten spoken words performed once, now also assessing set-shifting capacity) and third by ‘word list A delayed’ (delayed recall of wordlist A performed once later during the testing); mental set-shifting and cognitive information speed processing are tested by ‘verbal fluency’ (alternating naming of terms belonging to two different categories within one minute), inhibitory control is captured by a stroop test called ‘interference’. The MuSIC score ranges from 0 to 30; a score below 20 is considered indicative of CI which has been validated in 80 controls and 158 patients with MS [18]. In our center, the treating physician assumes cognitive preservation (CP) in the absence of any indication for CI which is routinely based on his and the patient’s impression as well as on the result of the screening battery MuSIC. In case of an indication of CI, detailed neuropsychological assessment (NPA) by an experienced neuropsychologist (LT) is recommended. During NPA, the following domains are evaluated: (a) short- and long-term memory by Verbal Learning and Memory Test (VLMT), (b) memory span and working memory (verbal and visual domain) by Wechsler Memory Scale—Revised (WMS-R), (c) information processing speed by Trail Making Test A (TMT A), (d) attention by Tests of Attentional Performance (TAP, subtests Alertness and Divided Attention) and Test of Attention D2, and (e) executive functions by Trail Making Test B (TMT B) and Regensburger Test of Word Fluency (subtests category—and letter fluency). To classify patients with NPA, raw scores of neuropsychological test results are converted to percentile ranks according to the normative population at different age levels. Normative values were adopted from established neuropsychological tests. When
available, normative values for German populations were used [20–24].

Inclusion and exclusion criteria

We studied three groups of subjects. 54 age-matched healthy controls, which had participated in other imaging studies at our institution, as well as CI and CP patients with MS. We decided to relate our measures of MS patients to those of healthy controls for reasons of quality and plausibility control. Figure 1 illustrates the selection of MS patients. In principle, we considered all patients included in TUM-MS and all patients referred to our center because of suspected CI (pre-selection). Then, we selected patients according to the inclusion criteria: availability of cognitive evaluation (either NPA or MuSIC, respectively; see below) and standardized MRI with an interval to cognitive evaluation of less than 365 days, age between 18 and 69 years, disease duration of less than 20 years, EDSS of less than 7.5, and exclusion of severe psychiatric comorbidity. For the selection of CI patients, CI had to be diagnosed by the neuropsychologist (LT) through detailed NPA. In accordance with the German guidelines on neuropsychological evaluation [25], a documented performance score of below −1z in at least two domains was used as an additional inclusion criterion for quality assurance. For the selection of CP patients, we assumed CP in case the treating physician had not documented any indication of CI; further, results of the cognitive screening test MuSIC not indicating CI (i.e., values >19) had to be available. Next, we applied the exclusion criteria, these were unusual MRI findings, violations of the MRI protocol, or limited examination conditions. From the patients with NPA, 2 were excluded due to MRI findings not typical for MS (diffuse leucencephalopathy, 1 tumefactive lesion), 5 due to limited examination conditions (2 language barriers, 2 non-compliant, 1 aggravation), and 19 as CI was not confirmed by NPA. From the CP patients, 4 were excluded due to other MRI findings (1 tumefactive lesion, 2 with artifacts, and 1 with cropped slices). Eventually, we included 51 patients.

Fig. 1 Flowchart of the selection process of patients. See text for details. (Asterisk) Inclusion criteria: brain scan with the same standardized MRI protocol, interval between the date of MRI and cognitive testing <365 days, age between 18–69 years, disease duration <20 years, Expanded Disability Status Score <7.5, and exclusion of severe psychiatric comorbidity. (Double asterisk) Limited examination conditions: language barrier, 2; non-compliant, 2; aggravation, 1. CI cognitive impairment, CP cognitive preservation, NPA detailed neuropsychological assessment, MuSIC Multiple Sclerosis Inventory Cognition, TUM-MS prospective observational study in MS at Technical University of Munich
with confirmed CI and 391 patients with CP before data analysis was started.

Image acquisition and processing

All brain images were acquired on the same 3 T scanner (Achieva, Philips, The Netherlands). We used a 3D gradient-echo T1-weighted sequence (orientation, 170 contiguous sagittal 1 mm slices; field of view, 240×240 mm; voxel size, 1.0×1.0×1.0 mm; TR, 9 ms; TE 4 ms) and a 3D fluid-attenuated inversion recovery (FLAIR) sequence (orientation, 144 contiguous axial 1.5 mm slices; field of view, 230×185 mm; voxel size, 1.0×1.0×1.5 mm; TR, 10,000 ms; TE, 140 ms; TI, 2750 ms).

A detailed description of image processing was given previously [26]. In short, WML were segmented from FLAIR and T1-weighted images by the lesion growth algorithm as implemented in version 2.0.15 of the lesion segmentation tool (LST, www.statistical-modelling.de/lst.html) for SPM12 (https://www.fil.ion.ucl.ac.uk/spm). Furthermore, we applied the computational anatomy toolbox (CAT12, version 916, https://dbm.neuro.uni-jena.de/cat/) as implemented in SPM12 after lesion filling to generate normalized, modulated, and smoothed GM images (Gaussian Kernel of 8 mm) for voxel-based morphometry. For the analysis of WML location, normalized WML maps were smoothed and interpreted as WML probability maps (Gaussian kernel of 12 mm) as suggested earlier [27]. Using CAT12 segmentations and publicly available atlases as implemented in CAT12, we also determined volumes of cortical GM, thalamus, putamen, caudate nucleus, hippocampus, amygdala, nucleus accumbens, corpus callosum, global WM, and cerebellar cortex; to account for differences in head size, we extracted total intracranial volume (TIV) by a reverse brain mask method [28]. For normalization, GM volumes were not only divided by the individual TIV but also multiplied by the mean TIV (of all groups) in order not to change the order of magnitude of volumes [29]. In addition, we used CAT12 to render and analyze surface-based cortical thickness maps [30]. We recently validated this technique in MS patients [31]. For smoothing of surface images, we used a Gaussian Kernel of 8 mm. We also extracted the individual mean cortical thickness values. Finally, we studied the collinearity of extracted structural brain parameters by partial correlation analyses of all pairs of parameters. Age, sex, and EDSS were included in these partial correlation analyses.

Group comparisons of demographic and clinical parameters as well as brain volumes

Demographic, clinical, and MRI parameters of CI and CP MS patients were compared by unpaired t tests (age, disease duration, EDSS, MuSIC, and brain volumes) or Chi-square test (sex). WML volume was converted to the decadic logarithm (lgWML) to approach normal distribution. For group comparisons of brain volumes, we used general linear models adjusting for age, sex, and EDSS in these and further analyses (see below), correction for EDSS was applied as this parameter is the most established parameter of physical disability in MS; our rationale was that results surviving correction for EDSS are more likely to be related to CI, whilst results not surviving this correction may have another basis. Finally, we applied the Holm–Bonferroni correction to adjust for multiple testing [32]. As we extracted 12 brain volumes, uncorrected \( p \) values were multiplied by this number.

Voxel-wise and surface-based analyses

To investigate whole-brain GM without any a priori hypothesis on certain brain regions, we performed voxel-wise and surface-based group comparisons by SPM12/CAT12. Age, sex, and TIV were included in these analyses. To identify regional brain changes independent from overall disability as estimated by EDSS and independent from other structural brain changes, we repeated analyses with inclusion of one additional variable. This resulted in six further analyses with the additional variable of EDSS (voxel-wise and surface-based), lgWML (voxel-wise and surface-based) volume; cerebral cortex volume (voxel-wise) and thalamic volume (surface-based). To correct for multiple comparisons across the brain, we applied threshold-free cluster enhancement (TFCE) (https://dbm.neuro.uni-jena.de/tfce/) with a corrected \( p \) value of <0.05 [33]. Furthermore, we analyzed WML probability maps in a voxel-wise manner [34] to identify WML locations specifically associated with CI.

Determinants of cognitive impairment in multiple sclerosis

Volumes showing the strongest association with CI (after correction for multiple statistical comparisons and age, sex, and EDSS) were subjected to binary logistic regression with the response variable of cognitive impairment. In such analyses, effect sizes are typically given by the exponentiation of coefficients \( \text{Exp}(B) \) corresponding to the odds ratio per unit. To allow for an intuitive interpretation of effect sizes, we \( z \)-scaled explanatory variables (volumes) in a way that CI had higher \( z \) values than CP patients. We analyzed the main effects without and with interactions.

Software

Apart from voxel-wise and surface-based analyses, all statistical analyses were performed using version 26 of
IBM SPSS; p values < 0.05 were considered statistically significant.

Results

Group comparisons of demographic and clinical parameters and brain volumes

Our healthy control group was highly comparable to our patient groups with regard to age and sex (n = 54, age 39 ± 5.3 years, 39 females; all p values of group comparisons with CP and CI patients, > 0.1). As expected, almost all brain volumes were significantly lower in both patient groups than in the control group. Therefore, we only report the results of the comparisons between patient groups with MS (i.e., CP vs. CI). CI and CP patients did not differ significantly in age, sex and disease duration (Table 1). The latter (CI 5.4 ± 5.6 years) reflected an early disease stage. Compared to CP patients, CI patients showed higher disability as measured by EDSS (3.0 ± 1.7 vs. 1.6 ± 1.1, p < 0.001). As expected, performance in the cognitive screening test MuSIC was much lower in the 28 CI patients in which this test battery was available (20.4 ± 5.5 vs. CP MS patients: 26.7 ± 2.9, p < 0.001). CI patients showed higher WML volume (lgWML 1.14 ± 0.68 vs. 0.50 ± 0.57; corresponding to WML 32.1 ± 34.8 vs. 5.6 ± 9.1 ml) and lower GM volumes (all p values < 0.05 after correction for multiple testing, i.e., for the 12 volumetric parameters). Of note, effect sizes were largest for lgWML and thalamic volume (standardized β value 0.25 and − 0.25). Less pronounced, we also observed highly significant atrophy of the corpus callosum. Within the patients, all pairs of structural brain parameters were significantly correlated (Fig. 2). Among the parameters with the strongest association to CI, thalamic volume and WML showed the strongest correlation (r = − 0.67, p < 0.001).

Table 1 Demographic, clinical, and MRI parameters of cognitively preserved and cognitively impaired patients with multiple sclerosis

| Parameter                   | CP (n = 391) | CI (n = 51, lest indicated otherwise) | Comparisons between CP and CI |
|-----------------------------|-------------|---------------------------------------|-----------------------------|
| Age (years)                 | 39 ± 9.8    | 38 ± 9.2                              | 0.43                        |
| Sex (male/female)           | 164/227     | 24/27                                 | 0.49                        |
| Disease duration (years)    | 4.1 ± 3.9   | 5.4 ± 5.6                             | 0.11                        |
| EDSS                        | 1.6 ± 1.1   | 3.0 ± 1.7                             | 2.3E-14                    |
| MuSIC                       | 26.7 ± 2.9  | 20.4 ± 5.5 (n = 28)                   | 2.9E-22                    |
| TIV (ml)                    | 1509 ± 154  | 1515 ± 154                            | 0.82                        |

Set of covariates: Age, sex, EDSS

| Parameter                   | Value       | p value    | Standardized beta |
|-----------------------------|-------------|------------|-------------------|
| lgWML                        | 0.50 ± 0.57 | 1.14 ± 0.68| 1.5E-7            |
| WML (ml) (range; median)     | 5.6 ± 9.1 (0.02–62.3; 3.4) | 32.1 ± 34.8 (0.23–141; 19.5) | 0.25              |
| Mean cortical thickness (mm) | 2.494 ± 0.10 | 2.421 ± 0.13 | 5.6E-5            |

Set of covariates: Age, sex, TIV, EDSS

| Parameter                   | Value       | p value    | Standardized beta |
|-----------------------------|-------------|------------|-------------------|
| Cerebral cortex (ml)        | 579 ± 39.1  | 555 ± 51.6 | 2.2E–5            |
| Thalamus (ml)               | 8.52 ± 1.50 | 6.82 ± 2.36| 1.7E–7            |
| Putamen (ml)                | 8.76 ± 1.00 | 7.98 ± 1.24| 1.3E–5            |
| Caudate (ml)                | 6.81 ± 0.92 | 6.22 ± 1.17| 0.0004            |
| Hippocampus (ml)            | 6.52 ± 0.57 | 6.22 ± 0.66| 0.001             |
| Amygdala (ml)               | 3.11 ± 0.28 | 2.96 ± 0.34| 0.004             |
| Nucleus accumbens (ml)      | 0.81 ± 0.09 | 0.77 ± 0.10| 0.004             |
| Cerebellar cortex (ml)      | 91.4 ± 8.02 | 86.5 ± 8.94| 0.002             |
| WM (ml)                     | 515 ± 29.1  | 499 ± 31.1 | 0.001             |
| Corpus callosum (ml)        | 18.4 ± 2.17 | 16.4 ± 3.24| 2.6E–5            |

The two columns on the right indicate differences between cognitively impaired and cognitively preserved patients. Demographic, clinical, and basic MRI parameters were compared by unpaired t tests or Chi-square test (sex). Brain volumes (scaled by TIV) were compared by general linear models after inclusion of the covariates (control variables) of age, sex, and EDSS. Highest absolute standardized β values are marked in bold. Values are given in mean ± standard deviation, lest indicated otherwise.

CI cognitively impaired, CP cognitively preserved, EDSS Expanded Disability Status Scale, MuSIC Multiple Sclerosis Inventory Cognition, TIV total intracranial volume, lgWML decadical logarithm of WML, WML white matter lesions.
Voxel-wise and surface-based analyses

Voxel-wise analyses of GM yielded a wide-spread GM decrease in CI compared to CP most pronounced in deep GM. Adjusting for EDSS weakened but did not fundamentally change the result (Fig. 3a, b). Regional analyses of cortical thickness revealed wide-spread cortical thinning in the CI group which was only slightly weakened after adjusting for EDSS (Fig. 4a, b). Aiming at parameters exerting an independent effect on CI, we repeated the voxel-wise and surface-based analyses after inclusion of image-based covariates. In the voxel-wise analyses, thalamic atrophy remained significant after inclusion of cortical atrophy (Fig. 3c) but almost disappeared after inclusion of WML volume (Fig. 3d). Reduced cortical thickness lost significance primarily in the occipital and parietal cortex after inclusion of either thalamic volume or WML, whilst large areas of reduced cortical thickness in frontal and anterior temporal areas remained significant (Fig. 4c, d).

To better visualize areas with most pronounced cortical thinning, we lowered the statistical threshold to a p value of <0.05 family-wise error corrected at the voxel level revealing eight areas: bilateral parahippocampal gyrus (1 and 2), left superior frontal gyrus (3), rostral middle frontal gyrus (4), left middle superior temporal gyrus including transverse temporal gyrus (5), right precentral gyrus (6), right middle temporal gyrus (7), and right supramarginal gyrus (8).

Voxel-wise analyses of WML probability maps did not yield meaningful results. The higher WML volume of CI patients was evenly and symmetrically distributed around the ventricles reflecting the spatial WML pattern typical for MS (not shown).

Determinants of cognitive impairment in multiple sclerosis

Here, we focused on the volumes showing the largest effects of CI, namely WML and thalamic volume. Both volumes were strongly correlated in both CP and CI patients (r = -0.560 and r = -0.808, respectively; both p < 0.001). Including the main effects of thalamic volume and WML volume in one binary logistic regression model with the response variable CI/CP (reference variable CI), only WML showed a significant contribution to CI. Including both main effects and their interaction in another model resulted in a higher pseudo-R2 value (suggesting a better model fit) and significant effects of WML volume and its interaction with thalamic volume (Table 2, upper part). Both models remained significant as described after the inclusion of overall disability estimated by EDSS (Table 2, lower part).
Discussion

We aimed to study brain structures critically involved in MS-related CI by investigating a large cohort of MS patients with available cognitive testing, including confirmation of CI in 51 patients by detailed NPA, and high-resolution MRI. This enabled us not only to identify related brain structures but also to estimate their effect sizes and to analyze their differential contributions as well as their relation to each other. We will consider our study design and cohort, then discuss the results focusing on WML and thalamic atrophy, and finally, acknowledge limitations.

This study was part of our TUM-MS in-house observational study on MS planned in 2007. Data collection was...
performed according to a standardized protocol for regular outpatient visits. CP was assumed in patients without any indication of CI according to the treating physician who routinely considers his and the patient’s impression as well as the result of the screening battery MuSIC. For quality assurance, we further applied the commonly accepted cut-off score of the MuSIC test battery for CP [18]. Although analyzed and not confirmed in the original publication [18], this score may still be influenced by the other factors apart from CI in MS, such as educational level. Therefore, this threshold may have introduced a bias towards higher premorbid intellectual capacity in the CP group. In contrast, CI of all included patients was confirmed through detailed NPA by an experienced neuropsychologist. Although in accordance with the Germany guideline on neuropsychological evaluation [25], our criterion, again introduced in retrospect for quality assurance, of a documented performance score below $-1\sigma$ in at least two domains is liberal compared to other studies [4–9, 11]. However, in these studies, cohorts with higher EDSS and longer disease durations were investigated (more than 10 years [4, 6–9, 11] and more than 7 years [5], respectively). Therefore, we believe that our CI patients were in the early stages of both MS and CI and that CI was milder than in patients of other studies. This may also explain why CI frequency was relatively low in our cohort compared to the frequency of 43–70% reported in the literature [35], where, again, most cohorts were in later stages of MS than our cohort. To conclude, we could analyze a large group of patients with comparatively mild but thoroughly confirmed CI, whilst we cannot fully exclude that a few patients of the even larger group of patients, classified as CP, were actually CI, which would have decreased statistical power rather than leading to false-positive results.

Comparing CI to CP patients, differences of three parameters stood out—all well in accordance with the literature: overall disability (i.e., EDSS) [12], WML volume, and

| Set of covariates | Left hemisphere | Right hemisphere |
|-------------------|-----------------|------------------|
|                   | Lateral         | Medial           | Lateral         | Medial           |
| A Age, Sex, TIV   | ![Image A](imageA.png) | ![Image A](imageA.png) | ![Image A](imageA.png) | ![Image A](imageA.png) |
| B Age, Sex, TIV, EDSS | ![Image B](imageB.png) | ![Image B](imageB.png) | ![Image B](imageB.png) | ![Image B](imageB.png) |
| C Age, Sex, TIV, Thalamus | ![Image C](imageC.png) | ![Image C](imageC.png) | ![Image C](imageC.png) | ![Image C](imageC.png) |
| D Age, Sex, TIV, lgWML | ![Image D](imageD.png) | ![Image D](imageD.png) | ![Image D](imageD.png) | ![Image D](imageD.png) |

**Fig. 4** Group comparison of cortical thickness. Group comparison of cortical thickness between cognitively impaired and cognitively preserved patients with multiple sclerosis after adjusting for different covariates. a Significant cortical thinning in cognitively impaired compared to cognitively preserved patients with multiple sclerosis is depicted after adjusting for age, sex, TIV; b after additionally adjusting for disability; c after additionally adjusting for thalamic volume; d and after additionally adjusting for white matter lesion volume. The left and right hemispheres are shown separately. Increasing significance is color-coded from dark red to light yellow, the latter indicating more cortical thinning. The statistical threshold was set to $p < 0.05$ corrected (threshold-free cluster enhancement). EDSS Expanded Disability Status Scale. lgWML decadic logarithm of white matter lesion volume, TIV total intracranial volume.
thalamic atrophy \([4–11]\). In addition, voxel-wise analyses confirmed that thalamic atrophy is the most striking difference between CI and CP patients within brain GM, whilst none of the areas of CI-related cortical thinning showed an effect size in this order of magnitude. Although associations of both WML load and thalamic atrophy with CI in MS had been demonstrated before by further evidence \([29, 36–40]\), we were impressed by the robustness of these effects compared to the remaining results. In addition, both parameters were strongly correlated, which had been reported before \([27, 41, 42]\) although not consistently \([43]\). Against this background, we felt that further analyses focusing on these two parameters were justified. In a common model, only WML volume independently explained the occurrence of CI. Of note, the inclusion of the interaction term of WML volume and thalamic atrophy led to a better overall model fit indicating significant contributions of WML volume and its interaction with thalamic volume. In other words, thalamic atrophy seems to be less problematic than WML, whilst co-occurrence of the two is detrimental. In our opinion, the idea that thalamic atrophy is in part driven by WML through axonal transection of connecting fibers best explains our results \([27, 42, 44]\). Such an effect of WML on thalamic atrophy is likely to depend on overall volume, eloquence of location, and destructive power (i.e., the extent of axonal transection in a given WML volume). These three are also very likely to increase the occurrence of CI in MS. Hence, we speculate that, in our statistical model, the main effect of WML volume reflects the spatial extent of WML load, whilst the interaction of thalamic and WML volume reflects the destructiveness of WML and their eloquence of location. In contrast, we were unable to demonstrate an independent main effect of thalamic volume in our cohort of patients, who were primarily in the early stages of MS. Yet direct thalamic damage through MS-related pathology exists \([45]\) and may become prominent in later stages.

With regard to the cerebral cortex, we observed widespread thinning in patients with CI compared to patients

| Explanatory variables: Thalamic volume, white matter lesion volume | Model with main effects only | Model with interactions and main effects |
|---|---|---|
| | Pseudo R2 Nagelkerke | \(p\) value | Pseudo R2 Nagelkerke | \(p\) value |
| Model fit | 0.23 | \(7.1E−13\) | 0.30 | \(9.9E−16\) |
| | Units for \(z\) scaling: standard deviation | OR per SD (95% CI) | \(p\) value | OR per SD (95% CI) | \(p\) value |
| Thalamic volume | – 152 µl | 1.30 (0.85–1.98) | 0.23 | 0.71 (0.41–1.23) | 0.22 |
| \(\lg WML\) | 0.62 (\(\pm\) 4.2 ml) | 2.77 (1.62–4.74) | 2E–4 | 2.54 (1.47–4.40) | 0.001 |
| Thalamic volume * \(\lg WML\) (interaction, \(z\) scores) | 1.21 | – | – | \(1.92 (1.44–2.70)\) | \(2.1E−5\) |

| Explanatory variables: Thalamic volume, White matter lesion volume, EDSS | Model with main effects only | Model with interactions and main effects |
|---|---|---|
| | Pseudo R2 Nagelkerke | \(p\) value | Pseudo R2 Nagelkerke | \(p\) value |
| Model fit | 0.31 | \(1.4E−16\) | 0.37 | \(2.5E−19\) |
| | Units for \(z\) scaling: standard deviation | OR per SD (95% CI) | \(p\) value | OR per SD (95% CI) | \(p\) value |
| Thalamic volume | – 152 µl | 1.48 (0.94–2.33) | 0.09 | 0.78 (0.44–1.38) | 0.39 |
| \(\lg WML\) | 0.62 (\(\pm\) 4.2 ml) | 1.91 (1.07–3.41) | 0.03 | 1.86 (1.04–3.34) | 0.04 |
| Thalamic volume * \(\lg WML\) (interaction, \(z\) scores) | 1.21 | – | – | \(2.00 (1.44–2.79)\) | \(3.5E−5\) |
| EDSS | 1.3 | 1.98 (1.47–2.67) | 6E–8 | 2.07 (1.50–2.85) | 9.0E–6 |

Cognitive impairment (CI, 0; CP, 1) was used as dependent variable (reference variable CI). Thalamic and white matter lesion volumes, as well as EDSS, were used as explanatory variables. Beforehand, data were \(z\)-scaled in a way that the values of the CI group were larger than those of the CP group. We analyzed four models: (1) with inclusion of only main effects (middle columns), (2) with inclusion of both main effects and their interaction (right columns), (3–4) repetition of (1) and (2) after inclusion of EDSS. Significant interactions are given in bold.

\(\text{EDSS}\) Expanded Disability Status Scale, \(\lg WML\) decadic logarithm of white matter lesion volume, OR per SD odds ratio per unit, i.e., standard deviation, corresponding to exponentiation of coefficients, \(\text{Exp}(B)\); SD standard deviation.
with CP. Although to a lower extent, we could relate cortical regions (primarily temporal and frontal lobe regions) more specifically to CI by correction for WML volume or overall disability (i.e., EDSS). The resulting effect was very robust but not in the order of magnitude of thalamic atrophy or WML. In MS patients in stages as early as our cohort, cortical atrophy was related to CI in only few studies [9, 46], whilst this effect seems to become more robust in later stages [4, 9, 47, 48]. Of note, a recent study demonstrated reduced cortical GM volume as the only significant MRI predictor of cognitive decline over a period of 5 years in a cohort at a later stage (compared to our cohort) with a mean symptom duration of 15 years at baseline [29]. We, therefore, speculate that the effect of cortical thinning on CI in MS is smaller in the early stages and comes more and more into play in later stages.

We also found atrophy of corpus callosum in MS patients with CI compared to CP. As volumetry was performed from normalized T1w images after filling (inpainting) of WML, this effect cannot be fully explained by volume loss through WML within the corpus callosum. Atrophy of the corpus callosum has been consistently described before but in smaller cohorts and, again, in later stages of MS [14, 15, 17]. Because of its strongest correlation with overall WM volume, we believe that the corpus callosum volume is an informative marker of WM pathology which is well conceivable given the densely packed long-range WM fibers within this WM structure. In line with this notion, MS-related changes in the tissue structure of the corpus callosum have been demonstrated by several studies using diffusion-tensor imaging techniques [16, 49–52].

We acknowledge limitations of our study. The educational level was not available in our cohort and could hence not be accounted for. The tests used for detailed NPA are not commonly used in MS, which reduces comparability of our cohort with the other cohorts. We could relate our clinical data only to measures based on the conventional structural MRI, so that we were restricted to quantification of MS pathology by volumetry of brain structures and T2-weighted hyperintense WML, which certainly does not cover the whole spectrum of MS pathology. Studies using more advanced techniques have indeed found associations with other MR-based parameters such as cortical lesions detected through double inversion recovery sequences [53, 54], or WM integrity damage detected through diffusion-tensor imaging [36, 50, 55]. Furthermore, our region-wise analyses can only detect effects spatially overlapping across subjects; it does not account for network information [56]. Hence, damage to different brain regions (across subjects but impeding the function of the same network) is not covered by our analysis.

In summary, we found a robust association of regional cortical thinning, corpus callosum atrophy, WML volume, and thalamic atrophy with CI. It seems that, in early MS, brain WML is the main driver of CI, whilst co-occurrence of thalamic atrophy intensifies the effect of WML. Yet, our data also demonstrate that, in the early stage of MS, comparatively mild CI is already associated with tissue damage in different brain compartments underlining the need to take CI as serious as physical symptoms. We believe that, for specific therapies of CI in MS, a deeper understanding is key. Studies on large cohorts, well-characterized (i.e. standardized diagnosis and quantification of CI), examined with multimodal imaging techniques, ideally longitudinally, will be necessary and probably only feasible in multicenter trials.

Acknowledgements Open Access funding provided by Projekt DEAL.

Funding CE received funding from the Medical Faculty, Technical University of Munich (Kommission für klinische Forschung). MM received funding from the German Competence Network Multiple Sclerosis (German Ministry for Research and Education, 01GI1604A) and by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, Priority Program SPP2177, Radiomics: Next Generation of Biomedical Imaging—Project number 428223038). BH was supported by the German Research Foundation (SFB TR-128). VP was supported by Novartis (Oppenheim Förderpreis 2017).

Compliance with ethical standards

Conflicts of interest The authors declare that they have no conflict of interest. None of the authors reports conflicts of interest related to this work. C. Engl, Laura Tiemann, Sophia Grahl, M. Bussas, Paul Schmidt, Christian Gaser, Annkathrin Beer, and Claus Zimmer have nothing to disclose. Viola Pongratz received research funding from Novartis (Oppenheim Förderpreis 2017). J. Kirschke has received travel support from Kaneka Europe as well as speaker honoraria from Philips Healthcare. A. Berthele reports grants from Bayer Healthcare, personal fees from Biogen, Merck Serono, Teva, Novartis, and Genzyme, and compensations for clinical trials from Biogen, Novartis, Genzyme, Roche, Teva, and Alexion k. B. Hemmer has served on scientific advisory boards for F. Hoffmann-La Roche Ltd, Novartis, Bayer AG, and Genentech; he has served as DMSC member for AllergyCare; he or his institution have received speaker honoraria from Biogen Idec, Teva Neuroscience, Merck Serono, Medimmun, Novartis, Desitin, and F. Hoffmann-La Roche Ltd; his institution has received research support from Chugai Pharmaceuticals and Hoffmann-La-Roche; holds part of two patents; one for the detection of antibodies and T cells against KIR4.1 in a subpopulation of MS patients and one for genetic determinants of neutralizing antibodies to interferon β. M. Mühlau received research support from Merck Serono and Novartis.

Ethical standard The study was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments. The study protocol of the TUM-MS cohort study was approved by the local ethics committee.

Informed consent Patients gave written informed consent that their de-identified data are used for scientific purposes.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Sumowski JF, Benedict R, Enzinger C, Filippi M, Geurts JJ, Hamalainen P, Hulst H, Inglese M, Leavitt VM, ROCMA, Rosti-Otajärvi EM, Rao S (2018) Cognition in multiple sclerosis: state of the field and priorities for the future. Neurology 90:278–288
2. Rao SM, Leo GJ, Haughton VM, Sautinn-Faubert P, Bernardin L (1989) Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 39:161–166
3. Rao SM (1986) Neuropsychology of multiple sclerosis: a critical review. J Clin Exp Neuropsychol 8:503–542
4. Riccitelli G, Rocca MA, Pagani E, Rodegheer ME, Rossi P, Falini A, Comi G, Filippi M (2011) Cognitive impairment in multiple sclerosis is associated to different patterns of gray matter atrophy according to clinical phenotype. Hum Brain Mapp 32:1535–1543
5. Schoonehme MM, Hulst HE, Brandt RB, Strik M, Wink AM, Uitdehaag BM, Barkhof F, Geurts JJ (2015) Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis. Neurology 84:776–783
6. Gouveia A, Dias SP, Santos T, Rocha H, Coelho CR, Ruano L, Galego O, Diogo MC, Seixas D, Sa MJ, Batista S (2017) Cognitive impairment and magnetic resonance imaging correlates in primary progressive multiple sclerosis. Acta Neurol Scand 136:109–115
7. Eijlers AJ, Meijer KA, Wassenaar TM, Steenwijk MD, Uitdehaag BM, Barkhof F, Wink AM, Geurts JJ, Schoonehme MM (2017) Increased default-mode network centrality in cognitively impaired multiple sclerosis patients. Neurology 88:952–960
8. Meijer KA, Eijlers AJC, Douw L, Uitdehaag BMJ, Barkhof F, Geurts JIJ, Schoonehme MM (2017) Increased connectivity of hub networks and cognitive impairment in multiple sclerosis. Neurology 88:2107–2114
9. Pravata E, Rocca MA, Valsasina P, Riccitelli GC, Gobbi C, Comi G, Falini A, Filippi M (2017) Gray matter trophism, and depression in patients with multiple sclerosis. Mult Scler 23:1864–1874
10. Matias-Guiu JA, Cortes-Martinez A, Montero P, Pytel V, Moreno-Ramos T, Torquera M, Yuz M, Arrazola J, Matias-Guiu J (2018) Identification of cortical and subcortical correlates of cognitive performance in multiple sclerosis using voxel-based morphometry. Front Neurol 9:920
11. Uhler T, Krasensky J, Sobisek B, Blahova Dusankova J, Seidl Z, Kubala Havrdova E, Sormani MP, Horakova D, Kalinic T, Vaneckova M (2018) Cognitive clinico-radiological paradox in early stages of multiple sclerosis. Ann Clin Transl Neurol 5:81–91
12. Patti F, Amato MP, Troiano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Piccioni O, Luccichenti G, Group CS (2009) Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Mult Scler 15:779–788
13. Rossi F, Giorgio A, Battaglini M, Stomillo ML, Portaccio E, Goretti B, Federico A, Hakiki B, Amato MP, De Stefano N (2012) Relevance of brain lesion location to cognition in relapsing multiple sclerosis. PLoS ONE 7:e44826
14. Bergendal G, Martola J, Stawiarz L, Kristoffersen-Wiberg M, Fredrikson S, Almkvist O (2013) Callosal atrophy in multiple sclerosis is related to cognitive speed. Acta Neurol Scand 127:281–289
15. Granberg T, Martola J, Bergendal G, Shams S, Damangir S, Aspelin P, Fredrikson S, Kristoffersen-Wiberg M (2015) Corpus callosum damage and cognitive dysfunction in benign MS. Hum Brain Mapp 30:2656–2666
16. Mesaros S, Rocca MA, Riccitelli G, Pagani E, Rovaris M, Caputo D, Ghezzi A, Capra R, Bertolotto A, Comi G, Filippi M (2009) Corpus callosum damage and cognitive dysfunction in multiple sclerosis: results of a 17-year longitudinal study. Mult Scler 21:1151–1158
17. Yaldizli O, Penner IK, Frontzek K, Naegelin Y, Amann M, Papadopoulo A, Sprenger T, Kuhle J, Calabrese P, Radu EW, Kappos L, Gass A (2014) The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients. Mult Scler 20:356–364
18. Calabrese P, Kalbe E, Kessler J (2004) Das multiple sklerose inventarium cognition (MUSIC). Psychoneuro 30:384–388
19. Yildiz M, Tettenborn B, Radue EW, Bendfeldt K, Borgwardt S (2014) Association of cognitive impairment and lesion volumes in multiple sclerosis—a MRI study. Clin Neurol Neurosurg 127C:54–58
20. Aschenbrenner S, Tucha O, Lange K (2000) Regensburger Wort-flüssigkeits-Test: RWT. Hogrefe, Verl. für Psychologie, 1st ed. Göttingen; Bern; Toronto; Seattle
21. Brickenkamp R (2002) Test d 2: Aufmerksamkeits-Belastungs-Test. Hogrefe, 9th ed. Göttingen; [u.a.]
22. Helmstaedter CA, Lendt M, Lux S (2001) Verbaler Lern- und Merkfähigkeitstest: VLMT. Beltz Test, 1st ed. Göttingen
23. Reitan RM (1992) Trail Making Test. Manual for administration and scoring. AZ: Reitan Neuropsychology Laboratory, Tucson
24. Wechsler D (2000) Wechsler Gedächtnistest—revidierte Fassung. Huber, 1st ed. Bern; Göttingen; Toronto [u.a.]
25. Neumann-Zielke L, Bahlo S, Andrea D, Riepe J, Roschmann R, Schötzau-Fürwentsches P, Wetzig L (2004) German guide-line neuropsychologische evaluation. Zeitschrift Neuropsycholog 26:289–306
26. Biberacher V, Schmidt P, Selter RC, Perrepeainter V, Kowarik MC, Knieter B, Buck D, Hoshii MM, Korn T, Berthele A, Kirschke JS, Zimmer C, Hemmer B, Muhlau M (2018) Fatigue in multiple sclerosis: associations with clinical, MRI and CSF parameters. Mult Scler 24:1115–1125
27. Muhlau M, Buck D, Forschler A, Boucard CC, Arsic M, Schmidt P, Gaser C, Berthele A, Hoshi M, Jochim A, Kronsbein H, Zimmer C, Hemmer B, Ilg R (2013) White-matter lesions drive deep gray-matter atrophy in early multiple sclerosis: support from structural MRI. Mult Scler 19:1485–1492
28. Keihaninejad S, Heckemann RA, Fagiolo G, Symms MR, Hajnal JV, Hammers A (2010) A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T). Neuroimage 50:1427–1437
29. Eijlers AJC, van Geest Q, Dekker I, Steenwijk MD, Meijer KA, Hulst HE, Barkhof F, Uitdehaag BMJ, Schoonehme MM, Geurts JIJ (2018) Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study. Brain 141:2605–2618
30. Dahneke R, Yotter RA, Gaser C (2013) Cortical thickness and central surface estimation. NeuroImage 65:336–348
31. Righart R, Schmidt P, Dahneke R, Biberacher V, Beer A, Buck D, Hemmer B, Kirschke JS, Zimmer C, Gaser C, Muhlau M (2017) Volume versus surface-based cortical thickness measurements.
a comparative study with healthy controls and multiple sclerosis patients. PLoS ONE 12:e0179590
32. Brender R, Lange S (2001) Adjusting for multiple testing—when and how? J Clin Epidemiol 54:343–349
33. Smith MJ, Nichols TE (2009) Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. NeuroImage 44:83–98
34. Charil A, Zijdenbos AP, Taylor J, Boelman C, Worsley KJ, Evans AC, Dagher A (2003) Statistical mapping analysis of lesion location and neurological disability in multiple sclerosis: application to 452 patient data sets. NeuroImage 19:532–544
35. Chiavarotti ND, DeLuca J (2008) Cognitive impairment in multiple sclerosis. Lancet Neurol 7:1139–1151
36. Hulst HE, Steenwijk MD, Versteeg A, Pouwels PJ, Vrenken H, Utidehaa BM, Polman CH, Geurts JJ, Barkhof F (2013) Cognitive impairment in MS: impact of white matter integrity, gray matter volume, and lesions. Neurology 80:1025–1032
37. Kincses ZT, Ropele S, Jenkinson M, Khalil M, Petrovic K, Loftfelder M, Langkammer C, Aspeck E, Wallner-Blazek M, Fuchs S, Jehna M, Schmidt R, Vecsei L, Fazekas F, Enzinger C (2011) Lesion probability mapping to explain clinical deficits and cognitive performance in multiple sclerosis. J Neurosci 31:1681–689
38. Amato MP, Portaccio E, Goretta B, Zopoli V, Battaglini M, Bartolozzi ML, Stromillo M, Guidi L, Siracusa G, Sorbi S, Federico A, De Stefano N (2007) Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol 64:1157–1161
39. Benedikt RH, Weinstock-Gutman B, Fishman I, Sharma J, Tjoa CW, Bakshi R (2004) Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch Neurol 61:226–230
40. Zivadinov R, Sepic J, Nasuelli D, De Masri R, Bragadin LM, Tommasi MA, Zambito-Marsala S, Moretti R, Bratina A, Ukkama M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M (2001) A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 70:773–780
41. Bendfeldt K, Kuster P, Traud S, Egger H, Winkelhofer S, Mueller-Lenke N, Naegelin Y, Gass A, Kappos L, Matthews PM, Nicholls TE, Radue EW, Borghardt SJ (2009) Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis—a longitudinal voxel-based morphometry study. NeuroImage 45:60–67
42. Henry RG, Shieh M, Amirbekian B, Chung S, Okuda DT, Pelletier D (2009) Connecting white matter injury and thalamic atrophy in clinically isolated syndromes. J Neurol Sci 282:61–66
43. Eshagh A, Prados F, Brownlee WJ, Altmann DR, Tur C, Cardoso MJ, De Angelis F, van de Pavert SH, Cawley N, De Stefano N, Stromillo ML, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Vrenken H, Leurs CE, Killestein J, Piramer L, Piramer C, Ourislen S, Wheeler-Kingshott C, Chard D, Thompson AJ, Alexander DC, Barkhof F, Ciccarelli O, Group Ms (2018) Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol 83:210–222
44. Louapre C, Govindarajan ST, Gianni C, Madigan N, Sloane JA, Treaba CA, Herranz E, Kinkel RP, Mainiero C (2017) Heterogeneous pathological processes account for thalamic degeneration in multiple sclerosis: Insights from 7 T imaging. Mult Scler 2017:1352458517726382
45. Vercellino M, Plano F, Votta B, Mutani R, Giordana MT, Cavalla P (2005) Grey matter pathology in multiple sclerosis. J Neurol Neurosurg Psychiatry 74:1101–1107
46. Portaccio E, Amato MP, Bartolozzi ML, Zopoli V, Mortilla M, Guidi L, Siracusa G, Sorbi S, Federico A, De Stefano N (2006) Neocortical volume decrease in relapsing-remitting multiple sclerosis with mild cognitive impairment. J Neurol Sci 245:195–199
47. Morgen K, Sammer G, Courtney SM, Wolters T, Melchior H, Blecker CR, Oschsman P, Kaps M, Vaitl D (2006) Evidence for a direct association between cortical atrophy and cognitive impairment in relapsing-remitting MS. NeuroImage 30:891–898
48. Tillema JM, Hulst HE, Rocca MA, Vrenken H, Steenwijk MD, Damjanovic D, Enzinger C, Ropele S, Tedeschi G, Gallo A, Ciccarelli O, Rovira A, Montalban X, de Stefano N, Stromillo ML, Filippi M, Barkhof F, Group MS (2016) Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: a multicenter study. Mult Scler 22:901–909
49. Bodini B, Cercignani M, Khaleeli Z, Miller DH, Ron M, Penny S, Thompson AJ, Ciccarelli O (2013) Corpus callosum damage predicts disability progression and cognitive dysfunction in primary-progressive MS after five years. Hum Brain Mapp 34:1163–1172
50. Caligiuri ME, Barone S, Cherubini A, Augimeri A, Chiarico C, Trolta M, Granata A, Filippelli E, Perrotta P, Valentino P, Quattrone A (2015) The relationship between regional microstructural abnormalities of the corpus callosum and physical and cognitive disability in relapsing-remitting multiple sclerosis. Neuroimage Clin 7:28–33
51. Llufriu S, Blanco Y, Martinez-Heras E, Casanova-Molla J, Gabilondo I, Sepulveda M, Falcon C, Berenguer J, Bargallo N, Villoslada P, Graus F, Valls-Sole J, Saiz A (2012) Influence of corpus callosum damage on cognition and physical disability in multiple sclerosis: a multimodal study. PLoS ONE 7:e37167
52. Ozturk A, Smith SA, Gordon-Lipkin EM, Harrison DM, Shiee N, Pham DL, Caffo BS, Calabresi PA, Reich DS (2010) MRI of the corpus callosum in multiple sclerosis: association with disability. Mult Scler 16:166–177
53. Papadopoulou A, Muller-Lenke N, Naegelin Y, Kalt G, Bendfeldt K, Kuster P, Stoecklin M, Gass A, Sprenger T, Wilhelm Radue E, Kappos L, Penner IK (2013) Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis. Mult Scler 2013:96
54. Nelson F, Datta S, Garcia N, Rozario NL, Perez F, Cutter G, Narayana PA, Wolinsky JS (2011) Intracortical lesions by 3T magnetic resonance imaging and correlation with cognitive impairment in multiple sclerosis. Mult Scler 17:1122–1129
55. Dineen RA, Vilisaar J, Hlinka J, Bradshaw CM, Morgan PS, Constantinescu CS, Auer DP (2009) Disconnection as a mechanism for cognitive dysfunction in multiple sclerosis. Brain 132:239–249
56. Schoonheim MM, Meijer KA, Geurts JJ (2015) Network collapse and cognitive impairment in multiple sclerosis. Front Neurol 6:82